Sheba Chief Medical Officer: Ventilators can do harm

Dr. Eyal Zimlichman  / Photo: Tamar Matsafi, Globes
Dr. Eyal Zimlichman / Photo: Tamar Matsafi, Globes

Dr. Eyal Zimlichman tells "Globes" the virus has two common types. Ventilators help heal the first but do harm with the second.

Dr. Eyal Zimlichman, Deputy Director General, Chief Medical Officer and Chief Innovation Officer at Sheba Medical Center, Tel Hashomer explains that Covid-19 is a very misleading disease. "Every day we discover new information about the disease and I'm sure that in another three months we'll say to ourselves 'how come we didn't understand that.' This disease is so complicated and unique and really not like flu at all."

Zimlichman explains, "We in fact see two completely different appearances of the disease. There are actually three but two of them are common. In one you have to put the patient on a ventilator. In the second, the damage to the lungs is such that if you put them on a ventilator, it actually harms them. And we don't know at the moment which is which, although we try to distinguish between them by breathing pressures. This can explain why about 70-80% of patients put on ventilators are ultimately dying."

In addition to the two types of the disease, there is a third type that affects the heart as well as the lungs. Sheba Medical Center is currently working with a coronavirus database built for the hospital by MDClone, in cooperation with the Maccabi Health Services and Rambam Hospital, in order to try and understand as quickly as possible, which patients will develop which type of the disease so that they can anticipate a curative response and the right treatment to administer. "These insights that we have started forming in only the last few days, are provoking us into rethinking our protocols. We do not put every patient on a ventilator that we would have done according to the acceptable protocols related to the functioning of the lungs."

What distinguishes between the two types of the disease at the moment?

"On the one hand, we see underlying illnesses such as autoimmune diseases, diabetes, mean that patients have less physical reserves. Another factor is probably the immunological composition of the patient, which is influenced by both genetics and their medical history. These characteristics are also relevant for coping with flu. I think if we were able to identify who is at risk of suffering from the disease more severely and who more lightly, then we could ease up on the precautionary restrictions for those who are clearly at lower risk."

There was an interesting discussion a few days ago on whether to give patients blood thinners. What was that about?

"We have identified with this illness a trait that does not appear in any other disease and that is that there are many blood clots in the small blood vessels of the lung. Micro clots fill up the entire lung and block the blood capillaries. We haven't seen such a symptom by itself in any other disease. For the most part such a problem is large clots and large blood vessels, or small blood clots appear alongside large ones in diseases characterized by many clots throughout the body. This symptom of small blood clots in just the lung is most unique."

"We have seen this first of all in post-mortems. We can also see it in CT scans. We can identify overall clotting through a D-Dimer type test. We still don't know who is likely to have the clotting and if it is one of the factors predicting the difference between the two types of the disease but it certainly could well be that the patients with blood clots are the less good candidates for ventilators - we are examining this and every day we discover something new."

"Today we are already administering treatment against clots to the more severely ill patients with coronavirus but the question is what medication to give and in what dosage. We are currently trying to examine patients that arrive who are already taking blood thinners and see if their situation is any different from the other patients."

Do you think that it is perhaps true that there are already two mutations of the virus that cause two different diseases?

"At the moment we don't see different viruses, although it is tempting to think that, based on the various appearances of the disease, and also on the different responses to the virus in different countries. For example, in China the high level of Ferritin (a blood protein that contains iron and can rise during inflammations) seems to be a better predictor of a worsening situation than in Europe."

"You said that 70-80% of those on ventilators are dying. Does that mean that our mortality figures can be expected to jump soon?

"Yes. The number of deaths does not reflect the real situation. Fortunately, also the number of people on ventilators is not high but we estimate that at least 50% of them will end up in the fatality column."

Published by Globes, Israel business news - www.globes-online.com - on April 19, 2020

© Copyright of Globes Publisher Itonut (1983) Ltd. 2020

Dr. Eyal Zimlichman  / Photo: Tamar Matsafi, Globes
Dr. Eyal Zimlichman / Photo: Tamar Matsafi, Globes
Ella Kenan  credit: Yossi Cohen A fighter of fake news about Israel

Ella Kenan saw online denial of October 7 happening straightaway. "I realized we had 24 hours, or we were doomed"

Liron Horshi credit: Jonathan Bloom Wiz's talent manager nurtures $1b workforce

Wiz's $32 billion sale to Google was rooted in the cloud security product if offers but could not have been achieved without the quality of its employees built by human resources chief Liron Horshi.

Yoav Shoham  credit: Eyal Izhar Yoav Shoham: AI isn't too smart, it's too dumb

AI21 Labs founder and CEO Prof. Yoav Shoham talks to "Globes" about dubious doomsday predictions, what should really concern us, and what could make Israel a global AI leader.

Insightec COO and general manager Eyal Zadicario credit: Ness Productions After 25 years of losses Insightec focuses on profit

Insightec COO and general manager Eyal Zadicario tells "Globes" about himself and the Israeli ultrasound company's long battle to change the medical world.

Amit Shaked credit: Tomer Lesher Driven to succeed but balancing ambition with wellbeing

At just 14, cybersecurity company Rubrik VP Amit Shaked began a B.Sc. in Computer Science and Math and mapped out his entire future, which included IDF service in the 8200 unit, and an inevitable huge startup exit.

Dr. Ola Gutzeit  credit: Ketty Hakim The doctor breaking new ground in fertility

"We know nothing about the female reproductive system," says Dr. Ola Gutzeit of Rambam Hospital. She seeks to change that, and hence change IVF for the better.

Google CEO Sundar Pichai  crediit: Shutterstock Why Google is paying so much for Wiz

Lagging its competitors in cloud and AI, and facing challenges to its core advertising business, Google could be looking to spend its way out of trouble.

Prof. Douglas Irwin  credit: Inbal Marmari "We will all be poorer"

Prof. Douglas Irwin, an expert on international trade, talks to "Globes" about the impact of President Trump's tariffs policy, and what Israel can do about it.

Rooftop solar panels credit: Shutterstock Does it pay for homes to install rooftop solar panels?

As the Israeli government steps up efforts to encourage homeowners to produce their own electricity from rooftop panels, "Globes" investigates the advantages and pitfalls.

UnitedHealth founder Richard Burke credit: Ken Easley UnitedHealth founder: US health system is broken

In an exclusive interview Richard Burke talks about the murder of the company's CEO, Donald Trump, his love for Israel, and investment in Israeli startup Korro AI.

Left to right: Karin Goldberg, Einav Laser, Dr. Arseniy Lobov, Dr. Paola Antonello, Dr. Merav Shmueli, and Prof. Yifat Merbl (center in black)  credit: Weizmann Institute Israeli scientists' discovery could lead to new antibiotics

Prof. Yifat Merbl of the Weizmann Institute and her team have found a natural source of anti-microbial substances in the "garbage can" of human cells.

Peter Kash credit: personal photograph Peter Kash confident about cancer cure breakthrough

In Israel for IATI's MIXiii International Life Science and Health-Tech week, the US investor talks about his life science portfolio and the opportunities Israel must seize.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018